Global Psoriasis Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
TNF Inhibitors, Interleukins Inhibitors, and Others.By Type;
Plaque Psoriasis, Psoriatic Arthritis, and Others.By Product;
Tumour Necrosis Factor Inhibitors - Adalimumab, Infliximab and Etanercept.By Distrubution Channel;
Topicals - Over-The-Counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Psoriasis Treatment Market (USD Million), 2021 - 2031
In the year 2024, the Global Psoriasis Treatment Market was valued at USD 28,110.38 million. The size of this market is expected to increase to USD 49,535.08 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.4%.
The global psoriasis treatment market is experiencing robust growth driven by increasing disease prevalence, heightened awareness about the condition, and advancements in therapeutic options. Psoriasis is a chronic autoimmune disease characterized by red, scaly patches on the skin, affecting millions of people worldwide. The rising incidence of psoriasis, coupled with improved diagnostic capabilities, has led to a greater number of patients seeking medical care. Awareness campaigns and educational initiatives by healthcare organizations have also played a pivotal role in encouraging patients to pursue treatment, thereby expanding the market.
Advancements in psoriasis treatment have significantly improved the quality of life for patients. Traditional therapies such as topical corticosteroids and phototherapy have been complemented by newer, more effective systemic treatments, including biologics and small molecule inhibitors. Biologic drugs, which target specific components of the immune system, have been particularly transformative, offering substantial relief for moderate to severe cases of psoriasis. These innovations have not only enhanced treatment efficacy but also reduced the frequency and severity of side effects, making long-term management more feasible for patients.
Looking forward, the psoriasis treatment market is poised for further growth driven by ongoing research and development. Pharmaceutical companies are actively pursuing the development of novel therapies, including next-generation biologics and biosimilars, to improve patient outcomes and expand treatment options. Additionally, the integration of personalized medicine approaches, which tailor treatments based on individual genetic and molecular profiles, is expected to further refine and optimize psoriasis management. As these advancements continue to emerge, the global psoriasis treatment market will likely see sustained expansion, benefiting patients with more effective and targeted therapeutic options.
Global Psoriasis Treatment Market Recent Developments
-
In 2023, biologics continued to dominate the psoriasis treatment market due to high efficacy in managing symptoms. New product launches by major players like AbbVie and Novartis expanded their influence, aiming to meet increased demand for advanced psoriasis therapies.
-
In 2022, the U.S. FDA granted fast-track designation to new oral treatments targeting severe plaque psoriasis, spurring further innovation and investment in next-generation therapies for chronic psoriasis management.
Segment Analysis
The Global Psoriasis Treatment Market has been segmented by drug class, type, product, and distribution channel, each of which contributes to the overall dynamics of the market. The drug class segmentation plays a pivotal role in the treatment landscape, with biologics, corticosteroids, vitamin D analogs, and systemic therapies being the key classes of drugs used to manage psoriasis. Biologic drugs, particularly those targeting specific immune pathways, have seen significant growth, especially in the treatment of moderate to severe cases of plaque psoriasis and psoriatic arthritis. These biologics, which include TNF inhibitors, IL-12/23 inhibitors, and IL-17 inhibitors, have revolutionized treatment by offering more targeted and effective solutions for patients who do not respond to conventional therapies. As the understanding of the immunologic basis of psoriasis deepens, new drug classes continue to emerge, further expanding treatment options.
The type segmentation within the psoriasis treatment market highlights the different forms of psoriasis, each requiring specialized care. Plaque psoriasis remains the most common form and thus dominates the market, with treatments largely consisting of topical therapies for mild cases and biologics for more severe presentations. Psoriatic arthritis, which often accompanies psoriasis, is another critical segment, driving the demand for drugs that address both the skin and joint symptoms. Treatments for psoriatic arthritis often combine traditional DMARDs with biologics, allowing for better disease control and improved quality of life for patients. The "others" segment, which includes rare and severe forms like guttate psoriasis and erythrodermic psoriasis, also drives demand for innovative treatments, although these cases make up a smaller proportion of the market.
In terms of product segmentation, the psoriasis treatment market is heavily influenced by both prescription and over-the-counter (OTC) products. Prescription products, particularly biologic injections and systemic oral medications, dominate the market due to their effectiveness in treating severe and refractory cases of psoriasis. These products are generally administered in clinical settings or through homecare services. OTC products, which include topical treatments like creams, shampoos, and ointments, are widely used for mild to moderate psoriasis and cater to a large consumer base. With growing patient awareness and the increasing prevalence of psoriasis, the demand for both prescription and OTC products is expected to rise, offering a more diverse array of treatment options to meet varying patient needs.
The distribution channel segmentation reveals the crucial role played by hospitals, specialty clinics, pharmacies, and e-commerce platforms in delivering psoriasis treatments to patients. Hospitals are key players in administering advanced therapies, including biologics, for patients with severe cases of psoriasis. Specialty clinics, often focusing on dermatology and rheumatology, are important for managing both skin and joint symptoms, particularly in patients with psoriatic arthritis. Pharmacies, including both physical stores and online platforms, are essential in distributing OTC and prescription medications, providing patients with easy access to treatment. E-commerce platforms have increasingly become a significant channel, particularly for the sale of OTC products, providing convenience and accessibility to a broader audience. As the market continues to grow, these distribution channels will likely evolve, expanding access to a wider range of treatment options.
Global Psoriasis Treatment Segment Analysis
In this report, the Global Psoriasis Treatment Market has been segmented by Drug Class, Type, Product, Distrubution Channel and Geography.
Global Psoriasis Treatment Market, Segmentation by Drug Class
The Global Psoriasis Treatment Market has been segmented by Drug Class into Plaque Psoriasis, Psoriatic Arthritis, and Others.
Plaque psoriasis is the most common type of psoriasis and accounts for a significant share of the market. Treatments for plaque psoriasis typically include topical therapies, phototherapy, and systemic drugs. Topical treatments such as corticosteroids and vitamin D analogs remain widely used, while biologic agents targeting specific immune system pathways are increasingly being prescribed for moderate to severe cases. As the prevalence of plaque psoriasis continues to rise, particularly in developed countries, the demand for both conventional and novel treatment options is expected to grow.
Psoriatic arthritis, a chronic inflammatory condition that often occurs in conjunction with psoriasis, represents another key segment within the psoriasis treatment market. It involves inflammation of the joints and can cause pain, stiffness, and joint damage. The treatment approach for psoriatic arthritis usually combines medications that target both the skin symptoms of psoriasis and the joint inflammation. Disease-modifying antirheumatic drugs (DMARDs), biologics, and JAK inhibitors are commonly used to manage psoriatic arthritis. The increasing recognition of the impact of psoriatic arthritis on patients' quality of life has spurred the development of targeted therapies, leading to an expansion of treatment options for this segment.
The "others" segment encompasses the treatment options for less common forms of psoriasis, such as guttate psoriasis, inverse psoriasis, and erythrodermic psoriasis. While these forms of psoriasis are less prevalent than plaque psoriasis, they can be more severe and may require specialized treatment regimens. For these cases, therapies often involve a combination of systemic medications, biologics, and phototherapy. Given the diversity of psoriasis types and their varying severity, the "others" segment remains an important area for the development of new and effective treatments that cater to the needs of these patients.
The segmentation of the global psoriasis treatment market by drug class highlights the growing recognition of the different therapeutic needs of patients with various forms of psoriasis. As the understanding of psoriasis deepens, more targeted treatments are being developed to address the underlying immune system dysfunction that drives the disease. Biologics, in particular, are increasingly seen as a game-changer in the treatment of both plaque psoriasis and psoriatic arthritis. The continued innovation in psoriasis therapies, coupled with an increasing awareness of the condition's impact, is likely to drive substantial growth in all segments of the market, offering patients more effective and personalized treatment options.
Global Psoriasis Treatment Market, Segmentation by Type
The Global Psoriasis Treatment Market has been segmented by Type into Plaque Psoriasis, Psoriatic Arthritis, and Others.
Plaque psoriasis is the most common type, accounting for a significant portion of the market. It is characterized by the development of red, scaly patches on the skin, primarily on the scalp, elbows, and knees. Treatment for plaque psoriasis typically includes topical therapies, such as corticosteroids and vitamin D analogs, along with systemic treatments, including biologics and oral medications, for more severe cases. As the prevalence of plaque psoriasis continues to rise, the demand for effective therapies, especially biologics, is expected to grow significantly.
Psoriatic arthritis, which often occurs in conjunction with psoriasis, is another key type segment in the market. This condition involves inflammation of the joints, causing pain, stiffness, and potential joint damage. Psoriatic arthritis is typically treated with disease-modifying antirheumatic drugs (DMARDs), biologics, and nonsteroidal anti-inflammatory drugs (NSAIDs). Biologic therapies targeting specific immune pathways have revolutionized the treatment of psoriatic arthritis, providing significant relief to patients who do not respond to traditional treatments. As awareness of the condition increases and the market for biologics expands, psoriatic arthritis continues to drive growth in the psoriasis treatment market.
The "others" segment in the psoriasis treatment market includes less common forms of psoriasis, such as guttate psoriasis, inverse psoriasis, and erythrodermic psoriasis. These types of psoriasis, while less prevalent, can be more severe and difficult to treat. Treatment for these forms often requires a combination of therapies, including systemic medications, phototherapy, and biologic treatments. Guttate psoriasis, for example, is characterized by small, drop-shaped lesions, while erythrodermic psoriasis leads to widespread redness and shedding of skin. The "others" segment continues to play a crucial role in the development of new treatments, as patients with these rarer forms of psoriasis often have more limited treatment options available.
Overall, the segmentation of the psoriasis treatment market by type highlights the diverse therapeutic needs of patients with different forms of psoriasis. While plaque psoriasis remains the most common and widely treated type, the growing recognition of the impact of psoriatic arthritis and rarer forms of psoriasis is driving the development of more targeted and effective treatments. As research into the disease continues and new therapies emerge, the market for psoriasis treatments will expand to offer more personalized care for patients across all types of psoriasis.
Global Psoriasis Treatment Market, Segmentation by Product
The Global Psoriasis Treatment Market has been segmented by Product into Tumour Necrosis Factor Inhibitors, Anticholinergics and Vitamin D Analogues.
The global psoriasis treatment market is segmented into various product categories, including Tumor Necrosis Factor (TNF) inhibitors, anticholinergics, and vitamin D analogues, each addressing different aspects of the disease’s pathology. TNF inhibitors, such as infliximab, adalimumab, and etanercept, play a crucial role in managing moderate to severe psoriasis by targeting and neutralizing TNF-α, a cytokine involved in systemic inflammation. These biologics have significantly improved patient outcomes by reducing the severity and extent of psoriatic lesions and are often prescribed when traditional treatments fail to provide adequate relief. The high efficacy of TNF inhibitors has made them a cornerstone in the therapeutic landscape of psoriasis.
Anticholinergics, although less commonly associated with psoriasis treatment compared to other drug classes, are sometimes utilized to manage specific symptoms or comorbid conditions related to psoriasis. Their role is primarily supportive, helping to alleviate discomfort from symptoms such as pruritus. These medications work by blocking acetylcholine receptors, thereby reducing the secretion of sweat and other bodily fluids, which can be particularly beneficial for patients experiencing excessive sweating or itching due to their psoriatic condition. While not a frontline treatment, anticholinergics can complement other therapeutic strategies, enhancing overall patient comfort and quality of life.
Vitamin D analogues, such as calcipotriene and calcitriol, are a vital component of topical treatment regimens for psoriasis. These compounds work by modulating the proliferation and differentiation of keratinocytes, thereby reducing the hyperproliferation of skin cells characteristic of psoriasis. Vitamin D analogues are often used in combination with corticosteroids to enhance their therapeutic effect while minimizing potential side effects. Their use is particularly advantageous for patients with mild to moderate psoriasis or for those who prefer topical treatments over systemic therapies. The continued development and optimization of these analogues underscore their importance in the broader treatment paradigm of psoriasis, offering patients effective and well-tolerated options for managing their condition.
Global Psoriasis Treatment Market, Segmentation by Distrubution Channel
The Global Psoriasis Treatment Market has been segmented by Distrubution Channel into Topicals - Over-The-Counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids.
The global psoriasis treatment market is segmented into topicals, systemic therapies, and biologics, each addressing different severities and aspects of the disease. Topical treatments are often the first line of defense for mild to moderate psoriasis and include corticosteroids, vitamin D analogs, and other agents applied directly to the skin. These treatments help to reduce inflammation, slow skin cell turnover, and relieve itching. Despite their effectiveness in managing mild symptoms, topicals are generally insufficient for more severe cases and often serve as adjunctive therapy in comprehensive treatment plans.
Systemic therapies, including oral and injectable medications, are used for moderate to severe psoriasis and work throughout the body to reduce immune system activity and inflammation. Common systemic treatments include methotrexate, cyclosporine, and newer oral treatments like apremilast. These medications are more potent than topicals and can significantly improve symptoms but come with a higher risk of side effects, necessitating regular monitoring by healthcare providers. The systemic segment is essential for patients who do not respond to or cannot use topical treatments, providing a critical bridge between topical and biologic therapies.
Biologics represent the most advanced segment in the psoriasis treatment market, offering targeted therapy for moderate to severe cases that have not responded well to other treatments. Biologics are designed to specifically target molecules involved in the immune response, such as TNF-alpha, IL-12, IL-23, and IL-17. These drugs have revolutionized psoriasis management by providing significant and sustained symptom relief with a generally favorable safety profile. However, biologics are expensive and may not be accessible to all patients, highlighting the need for ongoing research and development to create more affordable biosimilars. The introduction and growth of biosimilars are expected to expand access to these effective treatments, making biologics a rapidly evolving and crucial component of the global psoriasis treatment market.
Global Psoriasis Treatment Market, Segmentation by Geography
In this report, the Global Psoriasis Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Psoriasis Treatment Market Share (%), by Geographical Region, 2024
The global psoriasis treatment market is segmented by geographical regions, with North America holding the largest market share. This dominance is primarily due to the high prevalence of psoriasis in the region, coupled with robust healthcare infrastructure and significant investments in research and development. The United States, in particular, has a substantial market presence, driven by the availability of advanced treatment options, high patient awareness, and extensive access to healthcare services. Additionally, the presence of major pharmaceutical companies and ongoing clinical trials contribute to the region's leading market position.
Europe represents the second-largest market share in the global psoriasis treatment market. Countries like Germany, France, and the United Kingdom are key contributors to this regional market. The growth in Europe is supported by the increasing adoption of biologics and novel therapies, coupled with favorable government policies and reimbursement scenarios. The European market benefits from a strong focus on research and development, with numerous collaborations between academic institutions and pharmaceutical companies aiming to improve treatment outcomes for psoriasis patients. Moreover, the rising awareness and diagnosis rates, along with the increasing prevalence of the disease, drive the market growth in this region.
The Asia-Pacific region is expected to witness the fastest growth in the psoriasis treatment market over the coming years. This growth is driven by the increasing prevalence of psoriasis, improving healthcare infrastructure, and rising healthcare expenditures in countries like China, India, and Japan. Additionally, the growing awareness about psoriasis and the availability of advanced treatment options are contributing to market expansion. The region also presents significant opportunities for market players to invest in untapped markets and develop cost-effective treatment solutions. Government initiatives to enhance healthcare access and the increasing focus on dermatological diseases further support the growth of the psoriasis treatment market in the Asia-Pacific region.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Psoriasis Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Disease Prevalence
- Advancements in Therapeutic Options
-
Rising Awareness and Diagnosis - Rising awareness and diagnosis are pivotal drivers in the global psoriasis treatment market, significantly contributing to its growth. Increased public awareness about psoriasis, driven by educational campaigns and advocacy efforts from healthcare organizations and patient groups, has led to more individuals recognizing symptoms and seeking medical advice. These initiatives have highlighted the importance of early diagnosis and treatment, reducing the stigma associated with the condition and encouraging patients to pursue appropriate care. As a result, the number of diagnosed cases has risen, expanding the patient pool requiring treatment.
The medical community's improved understanding of psoriasis has also played a crucial role in enhancing diagnosis rates. Advances in diagnostic tools and techniques have enabled healthcare professionals to more accurately identify psoriasis and its various forms. This has facilitated earlier intervention, which is critical for managing the disease effectively and preventing complications. Furthermore, the integration of dermatology and primary care practices has streamlined the referral process, ensuring that patients with psoriasis receive specialized care promptly. Increased training and awareness among healthcare providers have also contributed to the timely and accurate diagnosis of psoriasis, further driving market growth.
The heightened awareness and diagnosis of psoriasis have spurred pharmaceutical companies to invest in the development of new and improved treatment options. Recognizing the growing demand, these companies are focusing on research and development to introduce innovative therapies that offer better efficacy, safety, and patient compliance. This has led to a robust pipeline of potential treatments, including advanced biologics, small molecule inhibitors, and personalized medicine approaches. As awareness and diagnosis continue to rise, the market for psoriasis treatments is expected to expand, offering patients more effective and diverse therapeutic options.
Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
-
Stringent Regulatory Requirements - Stringent regulatory requirements present a significant challenge in the global psoriasis treatment market. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), enforce rigorous standards for the approval of new treatments to ensure their safety and efficacy. The approval process for new psoriasis drugs involves extensive clinical trials, comprehensive data analysis, and meticulous documentation, which can be time-consuming and costly for pharmaceutical companies. These stringent requirements, while crucial for patient safety, can delay the introduction of innovative therapies to the market.
The high cost and complexity of meeting regulatory standards can act as a barrier to entry for smaller biotech firms and limit the number of new treatments available to patients. Pharmaceutical companies must invest significant resources in research and development, clinical trials, and regulatory compliance, which can be particularly burdensome for novel and complex therapies like biologics. Additionally, post-marketing surveillance and pharmacovigilance obligations add to the ongoing costs and administrative burden, further impacting the market dynamics.
Despite these challenges, stringent regulatory requirements also present opportunities for companies that can successfully navigate the approval process. Successfully gaining regulatory approval can serve as a competitive advantage, providing market exclusivity and establishing a strong reputation for quality and safety. Companies that invest in robust clinical trial designs and comprehensive safety monitoring can expedite their approval timelines and enhance their market position. Moreover, the rigorous standards set by regulatory bodies ensure that approved treatments are safe and effective, ultimately benefiting patients and fostering trust in new therapies. As a result, while stringent regulatory requirements pose challenges, they also drive innovation and ensure high standards within the psoriasis treatment market.
Opportunities
- Development of Novel Therapies
- Growth of Biosimilars Market
-
Personalized Medicine Approaches - Personalized medicine approaches hold immense promise in revolutionizing the global psoriasis treatment market. Psoriasis is a heterogeneous disease with varying clinical manifestations and treatment responses among individuals. Personalized medicine aims to tailor treatment strategies based on patients' unique genetic, molecular, and clinical characteristics, optimizing therapeutic outcomes and minimizing adverse effects. Advances in genomics, transcriptomics, and other -omics technologies have enabled researchers to identify biomarkers associated with psoriasis susceptibility, severity, and response to treatment, paving the way for personalized medicine approaches in psoriasis management.
One key aspect of personalized medicine in psoriasis treatment involves pharmacogenomics, which examines how genetic variations influence drug metabolism, efficacy, and toxicity. By analyzing patients' genetic profiles, healthcare providers can identify genetic markers associated with treatment response and adverse reactions to specific medications, guiding treatment selection and dosing strategies. This approach not only improves treatment outcomes but also reduces the risk of adverse events and treatment discontinuation, enhancing patient safety and adherence to therapy.
Personalized medicine approaches extend beyond genetic factors to encompass clinical, environmental, and lifestyle factors that influence psoriasis pathogenesis and treatment response. Integrated multidimensional profiling of patients, including genetic, clinical, and environmental data, enables healthcare providers to develop comprehensive treatment plans tailored to individual patient needs. Additionally, digital health technologies such as mobile health applications and wearable devices facilitate real-time monitoring of disease activity and treatment responses, allowing for dynamic adjustments to treatment regimens. Overall, personalized medicine approaches have the potential to transform psoriasis care by delivering more precise, effective, and patient-centered treatment strategies.
Competitive Landscape Analysis
Key players in Global Psoriasis Treatment Market include:
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- UCB S.A.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Type
- Market Snapshot, By Product
- Market Snapshot, By Distrubution Channel
- Market Snapshot, By Region
- Global Psoriasis Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Disease Prevalence
- Advancements in Therapeutic Options
- Rising Awareness and Diagnosis
- Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
- Stringent Regulatory Requirements
- Opportunities
- Development of Novel Therapies
- Growth of Biosimilars Market
- Personalized Medicine Approaches
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Psoriasis Treatment Market, By Drug Class, By Product, 2021 - 2031 (USD Million)
- TNF Inhibitors
- Interleukins Inhibitors
- Others
- Global Psoriasis Treatment Market, By Type, By Product, 2021 - 2031 (USD Million)
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
- Global Psoriasis Treatment Market, By Product, 2021 - 2031 (USD Million)
- Tumour Necrosis Factor Inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Tumour Necrosis Factor Inhibitors
- Global Psoriasis Treatment Market, By Distrubution Channel, 2021 - 2031 (USD Million)
- Topicals
- Over-The-Counter (OTC) Topicals
- Topical Non-Steroids
- Topical Steroids
- Topicals
- Global Psoriasis Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Psoriasis Treatment Market, By Drug Class, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- UCB S.A.
- Company Profiles
- Analyst Views
- Future Outlook of the Market